DHAC
Alternative Names: 5,6-Dihydro-5-azacyctidine; NSC 26480; NSC 264880Latest Information Update: 06 Jan 1998
At a glance
- Originator National Cancer Institute (USA)
- Developer ILEX Oncology Inc; MGI Pharma
- Class Small molecules
- Mechanism of Action RNA methylation inhibitors; RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Mesothelioma; Prostate cancer
Most Recent Events
- 06 Jan 1998 Discontinued-I for Cancer in USA (Unknown route)
- 06 Jan 1998 Discontinued-II for Mesothelioma in USA (IV-infusion)
- 06 Jan 1998 Discontinued-II for Prostate cancer in USA (Unknown route)